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Current research depicts speciﬁc modes of immunity and energy metabolism as being interrelated
at the molecular, cellular, organ and organism level. Hence, whereas M2 (alternatively-activat-
ed) macrophages dominate insulin-sensitive adipose tissue in the lean, M1-skewed (classically-
activated) macrophages accumulate in parallel to adiposity in the obese, and promote inﬂam-
mation and insulin resistance, that is, meta-inﬂammation. The latest frontier of immuno-meta-
bolism explores the coregulation of energy metabolism and immune function within hematopoietic
cells. M1-skewed macrophages are sustained in edematous, hypoxic tissues by anaerobic gly-
colysis, whereas mitochondrial biogenesis and respiration dominates in M2 cells. We review the
underlying mechanisms and the consequences of the transition from M2 to M1 predominance in
adipose tissue, as well as the extracellular signals and transcription factors that control macro-
phage phenotypes and impose distinct metabolic modes.
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1. INSULIN SIGNALS SATIETY
All cells are dependent on the synthesis of ATP to perform energy-expending processes. Formation of ATP
from ADP requires energy which is provided by the stepwise enzymatic catabolism of macronutrients—
glucose, fatty acids (FA), and amino acids. Cells with functional mitochondria that are not deprived of
oxygen can generate great amounts of ATP from the oxidation of glucose and FAs, and of amino acids
in certain circumstances. In the absence of mitochondria (e.g., erythrocytes) and during ischemia/hypoxia
smaller quantities of ATP are synthesized—through the glycolytic pathway and anaerobic metabolism. The
intermittent nature of nutrient availability (prior to the industrial revolution) and the variation in an organ-
ism’s energy expenditure (for instance, at rest as opposed to during physical exertion or infection) neces-
sitated scenario-dependent metabolic modes of oxidation, storage and distribution of the aforementioned
energy substrates [2]. Unraveling the various processes that underlie differential substrate utilization/storage
onacellularorganandwhole-bodylevelisongoingandinstrumentalinthediagnosisandtreatment ofmeta-
bolic disorders.
The biochemical adaption to a meal—the postprandial state—is one example of a circumscribed
metabolic mode. With the rise in plasma concentration of glucose that follows carbohydrate ingestion,
cells appropriately switch off pathways of fatty acid, protein, and glycogen catabolism and upregulate their
uptake and oxidation of glucose. Presented with a supply of glucose that surpasses immediate energetic re-
quirements, metabolically active cells also respond by synthesizing energy stores: glycogen (by poly-
merizing glucose), fatty acids (de novo lipogenesis from glucose), and triglycerides (from fatty acids and
glycerol). Amino acids are spared from oxidation, being preferentially utilized in the synthesis of proteins.
Insulin is the major hormone responsible for orchestrating the postprandial switch in substrate utilization,
storage, and prioritization [3].
Insulin is a polypeptide hormone synthesized by a subgroup of pancreatic endocrine cells that reside
in the islets of Langerhans, the beta cells. In health, insulin secretion is coupled to the availability of ATP
within the beta cell. As in other functioning cells, the availability of energy-providing substrates determines
ATP production, and an increase in plasma glucose following ingestion of carbohydrates is the most pow-
erful stimulus for insulin secretion. Circulating insulin binds to its cognate receptor, which is prominently
expressed by highly metabolic organs/cells including muscle/myocytes, adipose tissue/adipocytes, and the
liver/hepatocytes. The activated insulin receptor transduces insulin’s signals via the insulin receptor sub-
strates (IRSs) and the MAPK cascades. Most of insulin’s metabolic effects are downstream to the IRSs. Ser-
ine protein kinases (e.g., Akt, atypical PKCs, mTOR) are targeted downstream to IRSs such as to modulate
the activity (through enzyme phosphorylation status) and expression (through transcription factor phospho-
rylation) of enzymes that execute insulin’s command to “utilize glucose now, build proteins and store energy
for the future.” As time passes since the last meal (i.e., the postabsorptive state), the plasma concentration
of glucose gradually decreases due to insulin-mediated uptake by muscle and adipose tissue. In response,
beta cells secrete less insulin. Nevertheless, insulin continues to regulate metabolism at low, postabsorptive
concentrations: it inhibits glucose production by the liver (gluconeogenesis) and the release of free
(nonesteriﬁed) FAs from adipose tissue (lipolysis) until glucose and insulin concentrations are very low.
2. MACROPHAGE VERSATILITY
Resident and inﬁltrating macrophages perform an impressive repertoire of functions, in health and in
response to injury and infection. Among other roles, macrophages execute phagocytosis and killing of an
array of infectious microorganisms, phagocytose tissue debris, apoptotic parenchymal cells and apoptotic
neutrophils, orchestrate the repair of wounded tissue, and serve as a bridge between the innate and adaptive
arms of immunity. In accordance with their diverse activities, macrophages acquire differential phenotypes,
dictated by the form, stage and site of insult [4, 5]. To a certain extent, the phenotypic plasticity of macro-
phages parallels and cooperates with that of CD4+ T-lymphocytes, which become polarized from a na¨ ıve
state towards a particular mode of immunity [5].
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Macrophage polarization was broadly divided to two opposing phenotypes following the lymphocyte
terminology (Th1 and Th2 subsets) and consisting of M1 and M2 (later subdivided to M2a-c) macrophages
[6, 7]. Brieﬂy, the M1 designation refers to the “classically-activated” macrophage that emerges during cell-
mediated immune responses. Interferon-γ (IFN-γ) and lipopolysaccharide (LPS) prime macrophages to
acquire the microbicidal and proinﬂammatory properties that characterize the M1 phenotype. Macrophage
receptors for cytokines and LPS signal through IKK and AP-1 to induce the expression of classic inﬂamma-
tory mediators, including tumor necrosis factor-α (TNF-α), chemokine (C-C motif) ligand 2 (CCL2/MCP-
1), and inducible nitric oxide synthase (iNOS) [8]. M1 macrophages are the ﬁrst line of defense against
intracellular pathogens and they stimulate Th1 polarization of CD4+ lymphocytes. On the other hand,
M1 cells can harm bystander parenchymal and immune cells through the generation of microbicidal
agents (reactive oxygen species (ROS), proteases, etc.) and further stimulation of other leukocytes. M2 or
alternatively-activated macrophages are the counterparts of Th2 lymphocytes and participate in immunity
against extracellular parasites, helminthes, and so forth. M2 cells display hyporeactivity to M1-type ligands,
such as LPS, and are considered to be anti-inﬂammatory. Macrophages convert to an M2 phenotype at the
later stages of an M1 response. This phenotype switch can take place following the engulfment of apoptotic
neutrophils (efferocytosis) as well as other signals [9]. As a result, macrophages initially downregulate their
proinﬂammatory activity and shift their function towards local resolution of inﬂammation and tissue repair.
Activation of macrophage STAT 6 by IL-4 and -13 via their surface receptors, as well as ligand-mediated
activation of peroxisome proliferator activating receptors (PPARs) are key signaling pathways mediating
M2 skewing and M1 inhibition. Most recently, STAT6 as well as PPARγ and δ were shown to cooperate in
regulating the gene transcription pattern speciﬁct oM 2[ 10].
The resolution of inﬂammation is a regulated series of events. For instance, specialized proresolving
lipid mediators (SPM), such as the lipoxins, resolvins, protectins, and maresin, are produced from the
same source as the proinﬂammatory eicosanoids (i.e., omega-3 and omega-6 polyunsaturated fatty acids)
by 12/15-lipoxygenase (12/15-LO) to directly promote the termination of inﬂammation and return to
homeostasis. Prostanoids andleukotrienesare synthesizedfrom long-chain polyunsaturatedfatty acidsearly
in inﬂammation, following cleavage of the latter from membrane phospholipids by cPLA2. Recent evidence
suggests that the omega-3-type SPMs are derived not from phospholipid fatty acids, but rather from free
(nonesteriﬁed), omega-3 polyunsaturated fatty acids that transudates from the circulation into edematous
tissues while bound to albumin [11].
Macrophages are instrumental in both mediating and responding to the resolution of inﬂammation,
as embodied by the recently described resolution-phase, CD11blow macrophages, now termed Mres (Ariel
et al., Front. Immunol. 2011). Recent studies [12–14] have indicated that these macrophages convert from
the M2 to the new Mres phenotype in molecular and functional terms. Moreover, these studies highlighted
the unique characteristics of this macrophage phenotype and hypothesized that its emergence would prevent
exacerbated outcomes of acute and chronic inﬂammation ([14] and Ariel et al., Front. Immunol. 2011).
3. INSULIN RESISTANCE
Too often, metabolic organs display a pathologic reduction in their responsiveness to insulin, that is, insulin
resistance (IR). In such a scenario, muscle and adipose tissue uptake less glucose from the blood after a
meal, and hepatocytes inappropriately generate glucose through gluconeogenesis and glycogenolysis. This
manifests as postprandial and fasting hyperglycemia, the deﬁning features of IR and Diabetes Mellitus
(DM). Whereas hyperglycemia is the most infamous consequence of IR, lipid and protein metabolism is
also perturbed, and tissues other than muscle, liver and fat also fail to respond to insulin [15]. Adipocyte IR
manifests as excessive release of free (nonesteriﬁed) fatty acids (FFAs). IR is detrimental because it results
in elevated glucose and FFA concentrations, and also due to impaired function of other insulin-sensitive
organs (e.g., endothelial dysfunction secondary to impaired insulin-induced vasodilation). Many acute and
chronic disease states are accompanied by IR, including serious infection and trauma, obesity, auto-immune
and endocrine disorders, and treatment with certain drugs [16, 17]. Type II diabetes mellitus (DM-II) occurs
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when beta cells fail to compensate for chronic IR by upregulating the secretion of insulin. The incidence
of DM-II is increasing as a result of the obesity epidemic. In addition, a signiﬁcant proportion of the
population displays characteristics of the metabolic syndrome and/or prediabetic states; IR is the underlying
pathophysiology in these conditions [16]. Thus, IR is a highly prevalent condition worldwide and across
age groups. The clinical consequences of long-standing IR include atherosclerosis, complications of DM
and certain cancers, underscoring the relevance of the condition.
The failure of the insulin receptor to propagate its signal despite the interaction with insulin (i.e., IR)
is a multifactorial phenomenon. Most commonly, IR is instigated by nutrient overload and/or by inﬂam-
mation. Proinﬂammatory cytokines (IL-1β,T N F - α and in certain scenarios, IL-6) and ROS are over-pro-
duced in the context of the inﬂammatory response and activate several serine kinases, particularly IKK
and JNK. Phosphorylation of particular IRS serine moieties by the aforementioned kinases precludes IRS
tyrosine phosphorylation by the Insulin Receptor’s inducible kinase activity [18]. Hence, IRS-dependent
signaling is attenuated. Indeed, TNF-α inhibition attenuates inﬂammation and improves insulin sensitivity
in rodent models and patients with rheumatoid arthritis [19]. Serine phosphorylation of IRSs is the generic
biochemical inducer of IR across cell types, although cell-speciﬁc variations occur when particular serine
kinase(s) isoform(s) are involved. Other non-mutually-exclusive mechanisms that underlie defective insulin
signaling are activation of SOCS3, an excess of “counterregulatory” mediators that oppose insulin action
(e.g.,glucagon,epinephrine,cortisol),increaseddenovosynthesisofDAGandceramidefromexcessFAs—
which activates Ca++-independent, novel PKC isoforms, and ER stress [15, 20–22].
Obesity, the most common cause of IR, is accompanied by a low-grade, chronic inﬂammatory
response in the circulation and within metabolic organs. Proinﬂammatory cytokines secreted by recruited
and resident macrophages in adipose tissue, the liver, and skeletal muscle are a pivotal link between inﬂam-
mation and abrogation of insulin signaling in adjacent metabolic cells. The coincidence of weight gain, a
chronic, low-grade inﬂammatory response and IR reﬂects a causal association and is referred to as meta-
inﬂammation [21]. Adipose tissue has been the focus of meta-inﬂammation, as described in the following
section. The involvement of resident and recruited macrophages in hepatic [23] and skeletal muscle IR is
reviewed elsewhere [24].
4. M2 To M1 PHENOTYPE SWITCH IN INSULIN RESISTANCE
Emerging evidence links macrophages phenotype to the degree of organ-speciﬁc and whole-body insulin
sensitivity, under normal conditions and in disease. In the lean state, the small numbers of macrophages
populating adipose tissue are of the M2 phenotype and are associated with tissue-speciﬁc and whole body
insulin sensitivity. Obesity, in contrast, is associated with accumulation of M1-type macrophages. The M1-
to-M2 ratio is inversely related to tissue-speciﬁc and whole body insulin sensitivity [25, 26].
Adipocytes are the functional parenchymal cells of adipose tissue. Adipocytes esterify FAs and
glycerol to form triglycerides, which are stored in lipid droplets so large that they compress the nucleus and
cytoplasmtotheperiphery.Adipocytesthatresideinwhiteadiposetissue(WAT)arededicatedtothestorage
ofFAswhenenergysubstratesareabundant(ininsulin-sensitivemammals),andtothereleaseofFFAstothe
bloodstream at times of scarcity or when energy requirements are increased. WAT also displays endocrine
functions and secretes a battery of adipokines that differentially regulate metabolism, congruent with the
body’s immediate energy requirements and substrate availability. WAT function is partially determined by
its location: subcutaneous and visceral WAT handles FAs and secretes adipokines in a differential manner
[27].
Obesity results from a prolonged positive energy balance, that is, an ongoing calorie intake that
signiﬁcantly exceeds energy expenditure. Weight gain in obesity is primarily a consequence of the accu-
mulation of FAs—from the diet or from de novo lipogenesis—stored as triglycerides in WAT. In humans,
WAT responds to an excessive supply of fatty acids through hypertrophy—predominantly an increase in
lipid droplet size—and to a lesser extent through differentiation of preadipocytes into mature adipocytes
(i.e., hyperplasia [28]). The essential role played by adipocytes in metabolic homeostasis is underscored by
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certain human and rodent lipodystrophies, in which the scarcity of functional WAT culminates in IR, even in
the absence of overt obesity [29]. In diet-induced obesity itself, accrual of triglycerides per se is a relatively
benign process. However, adipocytes’ enzymatic and structural capacity to store FAs is eventually surpassed
by an ongoing surplus of calories [30]. In addition, the response of the adipose vasculature and stroma to
adipose expansion is often insufﬁcient, leading to hypoxia and overcrowding. As a result of the failure to
storeexcessFAs,theconcentrationofFFAs(particularlylong-chainsaturatedFAs)andoflipidssynthesized
from FAs (e.g., diacylglycerol and ceramide) increases to a harmful level. This perturbs adipocyte integrity
and function and may lead to apoptosis and necrosis [27, 31, 32]. Lipolysis is no longer inhibited (due to IR)
and adipocytes are unable to reesterify FAs, resulting in the spill-over of FFAs into the circulation. Excess
circulating free saturated FAs (FSatFAs) are harmful to the vasculature and also undergo ectopic deposition
in numerous organs, including liver and muscle. Insulin resistance and lipotoxicity ensue, as the capacity
of hepatocytes and myocytes to store triglycerides, is only a fraction of that of adipocytes. Obesity is also
associated with differential changes in adipokine secretion, such as a decrease in the insulin-sensitizing and
anti-inﬂammatory adiponectin, and an increase in leptin [22, 27, 32].
In addition to the metabolic and endocrine perturbations that parallel adipose expansion, AT is
gradually transformed into an inﬂamed organ, increasingly populated by proinﬂammatory myeloid- and
lymphoid-derived cells. Effectors of both innate and adaptive immunity are implicated in maintaining an
anti-inﬂammatory environment in the lean, as well as in the coupling of obesity to inﬂammation, and of
the latter to IR [21, 24, 31, 33]. While this paper focuses on M1- and M2-type macrophages in IR, other
immune cells that inﬂuence an organs’ responsiveness to insulin include CD4+ lymphocytes of the Th1,
Th2, and Treg phenotypes [34–38]a n dC D 8 + T-cells [39]. Of relevance to our discussion, lymphocytes
inﬂuence insulin sensitivity in part by differentially modulating the phenotype of macrophages that populate
the organ, and macrophage-lymphocyte cross-talk within metabolic tissues may substantiate or negate obe-
sity-associated inﬂammation and IR [24]. Inﬁltrating eosinophils [38] also contribute to adipocyte insulin
sensitivity in the lean, whereas mast cell accrual is implicated in adipocyte IR in obesity [40]. The
coincidence of increased adiposity, AT M1 macrophage accrual and IR, in concert with experiments in
which the modulation of AT macrophage recruitment/activation inﬂuences adipose and whole-body insulin
sensitivity indicates a causal link between AT inﬂammation and IR [21, 24].
In lean, healthy mammals, macrophages account for approximately 10% of AT cellularity and are
interspersed between adipocytes [41]. These cells are of the alternative phenotype, that is, they express
CD206, CD301a, and arginase-1 [42, 43]. M2 macrophages may indirectly contribute to adipocyte insulin
sensitivity by inhibiting the recruitment and polarization of their M1 counterparts, for example, through IL-
10 and IL-1RA (IL-1 receptor antagonist) production [43]. In addition, and in accord with their established
role in tissue remodeling, M2 macrophages may facilitate AT expansion in adaption to an increased
FA supply. For instance, M2 cells may regulate vascular and stromal modiﬁcations to sustain adipocyte
hypertrophy and hyperplasia [44] and secrete factors that promote preadipocyte differentiation [33]. There
is some evidence in support of the intriguing hypothesis that M2 macrophages directly enhance insulin
signaling in adipocytes [25, 45], although the factor(s) that mediate this modulation remain to be identiﬁed.
The lipolysis that appropriately occurs during weight loss is accompanied by a mild, transient inﬂux of
monocytes that mature into M2-type macrophages, which appear to counter excessive lipolysis [45]. The
AT chemo-attractant(s) and M2-derived factors that counter lipolysis of weight loss are not clear [46].
An emerging function of AT M2 cells is the clearance of FFAs released from adjacent adipocytes:
M2 macrophages upregulate their expression of proteins involved in the uptake (e.g., CD36, a fatty acid
translocase and scavenger receptor; [47]), esteriﬁcation (e.g., DGAT [48]), and oxidation (e.g.,L C A D[ 1])
of FAs. It may be that AT M2 cells thereby extract, catabolize, and/or store free FAs released by adipocytes
as neutral triglycerides, while avoiding the formation of large lipid droplets and lipotoxicity that occurs in
M1 cells in obesity [49]. A reduction in free FA concentration would attenuate IR and inﬂammation. Red
Eagle and Chawla recently postulated that in weight loss, M2 cells recruited to lipolytic adipocytes take up
large quantities of FFAs and transport them as intracellular, neutral lipids to the liver—a process akin to the
reverse transport of cholesterol by macrophages—rather than expose the portal and systemic circulation
2513TheScientiﬁcWorldJOURNAL (2011) 11, 2509–2529
to elevated levels of FFAs [46]. Further study may determine whether AT M2 cells transport FAs in this
manner to a quantitatively-substantial degree, in weight loss and/or maintenance of a lean body mass.
In a fascinating experiment, Wu et al. [38] infected mice fed a high-fat diet with a gastrointestinal
helminth (Nippostrongylus brasiliensis), which elicits a Th2-type response. Infection resulted in less AT
inﬂammation and attenuation of IR. Parasite infection is uncommon in the industrialized world—due to
sanitation and the eradication of malnutrition- and is unlikely to mediate M2 induction in lean AT. In
fact, the rarity of parasite infections has putatively contributed to the increase in immune-hypersensitivity
diseases (the hygiene hypothesis), possibly extending to obesity-induced inﬂammation and IR [50].
M2 skewing of AT macrophages in lean rodents maintaining their weight is attributed to the local
secretionoftheTh2cytokines,IL-4andIL-13,albeitatconcentrationslowerthanthoseaccompanyingovert
parasitic infection (Figure 1). The cellular source of these interleukins appears to be lean, “un-stressed”
adipocytes[25],recruitedeosinophils[38],andunique“innateTh2lymphocytes”[35].ATIL-10production
may also contribute to M2 recruitment and polarization [51]. Interestingly, insulin stimulates in vitro Th2
skewing of CD4+ lymphocytes—including a switch from IFN-γ to IL-4 secretion—possibly through ERK
phosphorylation [52]. It is, therefore, tempting to hypothesize that in the lean and insulin sensitive state,
insulin promotes triglyceride storage (rather than FFA release) in a dual manner: directly, through inhibition
of adipocyte lipases and indirectly, by maintaining adjacent macrophages in the alternative mode.
The intracellular pathways leading to the alternative activation of macrophages are gradually being
deciphered. Signaling through the IL-4 receptor-associated Janus kinases, IL-4 and IL-13 mediate the
rapid tyrosine phosphorylation of STAT6. Phosphorylated STAT6 dimerizes and translocates to the nucleus
where it transactivates the expression of the lipid-sensing nuclear factors PPAR-γ and PPAR-δ,a n dt h e i r
coactivator, the PPAR-γ coactivator-1beta (PGC-1β). Interestingly, PGC-1β serves as a coactivator for the
STAT6 dimer as well, thereby amplifying the expression of mouse M2-deﬁning molecules, such as CD206
and arginase-1 [10, 33, 53].
The PPARs form heterodimers with RXR (retinoid X receptor) and upon binding a lipid or synthetic
ligand they mediate gene expression through trans-activation. In general and in the context of the lean
AT macrophage, PPARs are instrumental in determining the metabolic mode of M2 macrophages, and in
inhibiting the M1 phenotype [26, 53]. Manipulation of PPAR-γ activity in macrophages provides evidence
of its link to AT M2 skewing and insulin sensitivity. For example, thiazolidinediones are synthetic PPAR-γ
agonists that attenuate IR in patients. This has been attributed to the PPAR-γ-dependent maturation of
subcutaneous adipocytes, which are associated with greater insulin sensitivity than visceral adipocytes
[27]. Notwithstanding the beneﬁcial redistribution of adipose tissue, it appears that macrophage PPAR-γ
is also necessary for the thiazolidinediones’ insulin-sensitizing effect [54]. Indeed, administration of a
thiazolidinedione attenuated the AT M1-to-M2 ratio, in conjunction with improved insulin sensitivity
[51, 55]. In contrast, disruption of PPAR-γ in myeloid cells impairs whole-body and AT M2 maturation
and activation, and predisposes mice to development of diet-induced obesity and IR [55]. A fraction of
activated PPAR-γ undergoes SUMOylation, without forming a heterodimer, and trans-represses the p50–
p65 (NF-κB) heterodimer [56]—an M1-dictating transcription factor. In contrast to p50–p65, the p50–p50
homodimer—induced, for example, by IL-10, promotes M2 skewing and M1 inhibition [57].
PPAR-γ binds polyunsaturated fatty acids that have been transformed by lipoxygenases and may
also be activated by the adipokine, adiponectin. Adiponectin is unique among the adipokines in that it exerts
insulin-sensitizing and anti-inﬂammatory effects, and in that its secretion is gradually reduced as adipose
tissue expands. In the lean state, adiponectin binds to its two cognate receptors expressed by metabolically
active cells, as well as monocytes and macrophages. As a result of signaling through PPAR-γ and AMP-de-
pendent kinase (AMPK) stimulation, adiponectin inhibits the M1 and promotes the M2 phenotype [58–
60]. Adiponectin also induces ceramidase in macrophages, thereby attenuating ceramide’s proinﬂammatory
effects [61]. Adiponectin’s M2-skewing and M1-opposing properties and the inverse correlation between
adiposity and adiponectin concentrations constitute an important link between body weight, macrophage
phenotype, and insulin responsiveness.
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FIGURE 1: Interdependence of adipocyte and macrophage functional modes in the lean and obese states.
The left side of the diagram depicts the insulin-sensitive adipocyte and M2-type adipose tissue macrophage
characteristic of adipose tissue in the lean state. Adipocytes are of a normal size and are sensitive to
insulin’s signal to minimize the cleavage of fatty acids from triglyceride stores (lipolysis). Consequently, local
and circulating concentrations of FFA are maintained below harmful levels. Healthy adipocytes (as well as
other cell types not shown here) are a source of M2-inducing cytokines—IL-4 and IL-13, which signal through
STAT6 phosphorylation to induce transcription of PPARs, their coactivator, PGC-1β, and 12/15-LO. PGC-1β
promotes the assembly of the STAT6 transcription complex, thereby amplifying the expression of signature
M2 proteins, such as arginase-1 and the pattern recognition/endocytic receptor CD206. Induction of 12/15-
LO further enhances the M2 phenotype and insulin sensitivity by synthesizing 15-HETE (from arachidonic
acid), 17S-HDHA, and RvD1 (the latter two from DHA). RvD1 is a specialized proresolution mediator and
appears to act on its cognate receptor (not shown) expressed on macrophages and adipocytes to promote
the M2 phenotype and to induce adiponectin secretion, respectively. Indeed, healthy adipocytes produce
and secrete greater amounts of adiponectin than in the obese, and this adipokine exerts insulin sensitizing
and anti-inﬂammatory effects, locally and systemically. Adiponectin signaling inhibits M1-skewing, enhances
PPAR-γ activity, and increases oxidative metabolism in adipose tissue macrophages. The ligand binding
domain of PPAR-γ recognizes oxygenated metabolites of polyunsaturated fatty acids which are consumed
in the context of a healthful diet, including 15-HETE and 17S-HDHA. Activated PPAR-γ inhibits NF-κB-
dependent gene expression. It also forms a heterodimer with RXR to induce proteins involved in the
uptake (e.g., CD36), esteriﬁcation (e.g., DGAT), and oxidation (e.g., LCAD) of FFAs released from adjacent
adipocytes. Consequently, the concentration of FFAs does not reach toxic levels. Free, extracellular DHA
contributes to M2-skewing by activating a novel surface receptor (GRP120). During weight gain, adipocytes
undergo hypertrophy in an attempt to store excess FAs as neutral lipids, that is, triglyceride. Unfortunately,
the excess supply of FAs eventually surpasses the capacity of adipocytes and adipose tissue to store lipids,
leading to an increase in FFA concentrations. The reduced sensitivity to insulin that accompanies obesity
also increases FA release by allowing lipolysis of triglycerides. In conjunction with LPS derived from the
abnormal intestinal ﬂora that populates the obese, and with M1/Th1-type cytokines, free saturated FAs
activate macrophage IKK and JNK1, thereby inducing the M1 immune program. M1 macrophages produce
IL-1β and TNFα, which increaseand activate adipocyte IKK and JNK to block insulin signaling. As a result,
the number of M1 macrophages parallels the expansion of adipose tissue, exacerbating inﬂammation and
insulin resistance.
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Whereas a diet rich in saturated fatty acids is detrimental to cardiometabolic health, consumption of
omega-3 polyunsaturated fatty acids (PUFAs: e.g., EPA and DHA, which are present in signiﬁcant amounts
in oily ﬁsh) is inversely associated with cardiovascular and metabolic disease [62]. Indeed, omega-3
PUFAs are essential nutrients, in virtue of their oxygenated metabolites that potently modulate multiple
cellular processes. EPA and DHA undergo enzymatic transformation by 12/15-LO and other enzymes
in the production of SPMs (such as Resolvin E1, Resolvin D1, and Protectin D1) and of intermediate
metabolites that are potent PPAR ligands [23, 63]. IL-4 and IL-13 induce 12/15-LO expression in murine
and human monocytes/macrophages [64–68] thereby promoting the production of SPM and PPAR-ligands
from DHA. Emerging evidence suggests that metabolism of long-chain omega-3 PUFAs by the 12/15-LO
pathway provides mediators that support M2-skewing of AT macrophages and stimulate adiponectin
production. Interestingly, these mediators also attenuate hepatic steatosis (excessive accumulation of
triglycerides in hepatocytes) and Kupffer cell activation in nonalcoholic fatty liver disease, the hepatic
component of the metabolic syndrome [23, 69]. Speciﬁcally, DHA administration attenuated inﬂammation
[70] in AT and the liver of obese rodents and reduced hepatic accumulation of triglycerides [71, 72]. AT
concentrations of DHA-derived SPMs, RvD1 and PD1, and of 17S-HDHA (an intermediate metabolite in
the 12/15-LO-dependent synthesis of SPMs) were increased by DHA ingestion, and 17S-HDHA was shown
to potently activate PPAR-γ and mimic the therapeutic effects of rosiglitazone. A study in mice that are
transgenic for fat-1, an enzyme that converts omega-6 to omega-3 PUFAs, conﬁrmed the beneﬁt conferred
by omega-3 PUFAs in obesity-induced AT perturbations. These mice displayed less obesity-induced IR
and AT M1 accumulation than their wild-type controls [73].
Obese adults treated with omega-3 fatty acids display higher adiponectin concentrations [74–76],
plausibly mediated in part by metabolism to RvD1 and RvE1, as administration of these SPMs increases
adiponectin secretion in obese rodents [72, 77]. RvD1, at the nanomolar range, also reduced the M1-to-M2
ratio in AT, at least in part through adiponectin induction. Interestingly, DHA and RvD1 also promoted
the emergence of proresolving macrophages [14, 78]. It was recently conﬁrmed that RvD1 enhanced non-
phlogistic phagocytosis and M2 marker expression by macrophages residing in the stroma-vascular com-
partment of obese AT [70]. Furthermore, intraperitoneal administration of DHA induced the emergence of a
low-expressing CD11b/F4/80 subset of macrophages in the adipose tissue of obese mice [70]. This suggests
that the Mres-like macrophages that emerge during resolution of zymosan-induced inﬂammation [14]m a y
also be induced therapeutically in the context of obesity-induced inﬂammation. The beneﬁcial impact of
DHA at high concentrations on M2 skewing and M1 inhibition of AT macrophages—and as a result on
AT function—is also mediated through direct stimulation of the macrophage cell-surface receptor, GPR120
[79]. Two recent reviews have addressed the pleiotropic effects of omega-3 FA consumption and conversion
to SPMs in ameliorating inﬂammation and insulin resistance in adipose tissue and the liver [23, 69]. A
clinical trial (NCT00760760) is presently assessing whether a similar beneﬁcial response occurs (i.e., a re-
d u c t i o ni nA Ti n ﬂammation) in morbidly obese adults ingesting ﬁsh oil capsules.
In summary, in the lean and the treated obese, several exogenous and endogenous factors target inter-
secting pathways in AT macrophages to inhibit classic activation and to induce M2 polarization (Figure 1).
There is ample evidence the M2 phenotype is causatively associated with adipocyte insulin sensitivity.
Incontrasttotheleanstateandtoweightloss,obesityisaccompaniedbyarobustinﬂuxofmonocytes
[80] which transform into M1 macrophages that induce adipocyte IR [81], recruit additional immune
cells, and exacerbate inﬂammation [82]. In addition to secreting cytokines and reactive oxygen species
(ROS) that antagonize insulin signaling, proinﬂammatory macrophages appear to inhibit adipogenesis
through presentation of Wnt5a, thereby curtailing the adaptive increase in cellular depots for FAs [83]. The
magnitude of AT macrophage accumulation during weight gain is remarkable, reaching 40% of AT cellu-
larity. These staggering statistics exemplify the concept of an inﬂamed adipose tissue. In contrast to macro-
phages recruited to the AT in weight loss, the macrophages detected in the obese continue to reside in
expanded subcutaneous and visceral WAT and maintain their proinﬂammatory status unless weight loss is
achieved [84, 85] and/or physical activity is increased [85].
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The inﬂamed adipose tissue of obesity resembles an organ chronically infected by an intracellular
organism, despite the absence of anypathogen. This raises the question of the identity of cells andmolecules
that attract monocytes to AT and impose the transformation to M1 macrophages. In 1993, Hotamisligil et
al. [86] demonstrated that the proinﬂammatory cytokine TNF-α was expressed by AT of obese, but not
lean rodents, and that TNF-α induced adipocyte IR through serine phosphorylation of IRSs by IKK. TNF-α
also stimulates the NH2-terminal kinase (JNK) pathway, a stress kinase that normally phosphorylates the
c-Jun component of the activator protein 1 (AP-1; c-jun-c-fos). JNK also phosphorylates serine residues
on the IRS, thereby inhibiting insulin signaling in adipocytes in concert with IKK (Figure 1 and [18]).
These data and subsequent studies led to a paradigm switch in the perception of AT and the adipocyte as a
tissue/cell of limited biologic repertoire beyond FA storage and release. In addition to the prototypical M1-
inducing cytokine, TNF-α, the chemokine CCL2 and its cognate receptor, CCR2 are also upregulated in
the adipose tissue of obese subjects and rodents [41, 87–89]. Indeed, selective deletion of CCR2 in myeloid
cells reduced the M1 prevalence of AT macrophages in the obese [89, 90].
As regards the cellular source of AT cytokines and chemokines, there is some evidence that hyper-
trophic,FFA-stimulated,andhypoxicadipocytesthemselvesareasourceofthesecytokinesandchemokines
[89]. In addition, adipocyte apoptosis may attract macrophages [26]. Whether this could be quantitatively
accountable for monocyte inﬂux is not clear and many authors believe that neither adipocyte apoptosis
nor secretion of cytokines/chemokines by adipocytes can fully account for macrophage inﬂux and M1
specialization [91].
Adipocyte necrosis is increased in the context of obesity. The observation that the vast majority of
inﬁltrating macrophages encircle necrotic adipocytes to form crown-like structures in obese rodents and
humans highly suggests that necrosis-associated factors chemo-attract monocytes [92, 93]. As previously
mentioned, monocytes acquire an M1 phenotype and secrete cytokines and ROS that interfere with insulin
signaling in adjacent adipocytes. As a result, lipolysis of triglycerides is not inhibited by insulin. In turn,
excessive release of FFA targets macrophage signaling to promote the proinﬂammatory output (as detailed
below). The paracrine cross-talk between adipocytes and macrophages thereby evolves into a partially self-
sustaining cycle of “M1-driven inﬂammation → adipocyte IR → increased FFA → M1-driven inﬂamma-
tion” that serves also to recruit more monocytes (see Figure 1 and discussion below) [94]. M1 macrophages
themselves are probably the major source of AT cytokines and chemokines in established obesity.
In infection, the activation of the TLR4 is central to the development of the M1 phenotype. Similar to
other TLRs, TLR4 detects speciﬁc PARPs (pathogen-associated recognition patterns). Macrophage TLR4
preferentially ligates LPS released from the outer membrane of Gram-negative bacteria (GNB). TLR4
signaling elicits ROS generation and nuclear translocation of canonical NF-κB, the p50–p65 heterodimer.
Indeed, GNB septicemia [17] and systemic administration of LPS [95, 96] induce an insulin-resistant state.
Furthermore, LPS infusion impaired insulin signaling and induced proinﬂammatory cytokine and che-
mokine expression in human subcutaneous AT [95, 96]. These ﬁndings suggest that LPS may mediate
M1 activation in obese AT. Whereas Gram-negative bacteremia is incapacitating and cannot account for IR
in the general population, emerging evidence now depicts obesity and DM as states of “metabolic endo-
toxemia,” that is, mildly elevated concentrations/activity of ﬂora-derived LPS detectable in the circulation.
The mechanisms underlying the mild endotoxemia include enhanced intestinal translocation of LPS from
intestinal microbes [97] and impaired LPS neutralization [98]. Indeed, the vast population of micro-
organisms residing in the intestine is emerging as a major regulator of gastrointestinal, metabolic, enter-
oendocrine, and immune function [50]. Obesity and DM are accompanied by an increase in LPS-containing
microbiota in the gut [99]. This impairs epithelial barrier function, precipitating the translocation of LPS,
macrophage inﬁltration of AT, and induction of adipose IR in a CD14-dependent manner [100, 101]. A
high-fat meal also facilitates absorption of intestinal LPS and promotes low-grade systemic [102]a n dA T
[101, 103]. The intestinal ﬂora can be safely manipulated through intake of probiotics and prebiotics such
as to augment insulin sensitivity [104]. We hypothesize that certain probiotic strains may ameliorate the
increased M1-to-M2 ratio of AT macrophages, thereby attenuating IR.
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In addition to LPS, FSatFAs (particularly lauric (C12:0), myristic (C14:0), and palmitic acids
(C16:0)) are ligands for TLR4 and TLR2. FSatFAs (but not free polyunsaturated FAs) activate these
receptors in monocytes, eliciting NF-κB-responsive gene transcripts in an MyD88-dependent manner [105–
107]. The detection of an endogenous ligand (FSatFA) by the macrophage pattern recognition receptors
(PRR), TLR4/TLR2, is in accordance with the role of macrophages (and other sentinels of the immune
system) in recognizing “danger signals” even in the absence of “nonself” entities [108]. A plausible mech-
anistic explanation for the ability of TLR4/2 to be activated by LPS and by FSatFA is that the latter mimics
the Lipid A moiety of Gram-negative bacteria (e.g., E. coli and S. typhimurium) LPS, which contains several
modules of lauric and myristic acid [109]. Of note, the stimulatory effect of FSatFAs on TLR4 is not limited
to immune cells. TLR4 is constitutively expressed by a diverse range of cells, including epithelial and endo-
thelial cells, hepatocytes, myocytes, and adipocytes. Palmitic acid (C16:0), for example, stimulated IKK
and induced IL-6 and TNF-α expression in both adipocytes and endothelial cells in a TLR4-dependent
fashion. Also of interest is that the long-chain omega-3 FA, DHA blocks the activation of TLR4/2 by LPS
or FSatFA, at least in vitro [105].
The plasma concentration of FSatFAs is typically elevated in diet-induced obesity, due to increased
intake, de novo lipogenesis (of palmitic acid), and resistance to insulin’s anti-lipolytic effect. Infusion of
lipids (triglyceride emulsion) and heparin (which activates lipoprotein lipase) elevates FFA concentrations
and induces IR in healthy adults [110]. This experimental model recapitulates the FSatFA-induced IR of
obesity, but does not directly implicate TLR4 activation, since FSatFAs may interfere with insulin signaling
through TLR4-independent mechanisms, such as an increase in DAG and induction of Endoplasmatic Stress
[20, 22]. The evidence implicating TLR4 in FSatFA-induced IR arises from studies in Tlr4−/− mice and
cells, demonstrating protection from obesity-induced AT inﬂammation and IR compared with their wild-
type counterparts [111, 112]. One may still argue that FSatFA-mediated adipose IR and inﬂammation is
elicited via adipocyte, rather than macrophage TLR4 signaling. The conﬁrmation that FSatFAs drive M1-
skewing in obese AT was provided by demonstrating that Tlr4 knockdown conﬁned to hematopoietic cells
attenuates the increase in AT M1 versus M2 markers [113] and the detection of a subpopulation of AT-
inﬁltrating macrophages that are classically activated by FSatFAs in obesity [114].
Interestingly, FSatFAs uptake into classically activated macrophages may be increased in IR, and
this appears to be associated with impaired insulin signaling in macrophages (which express the insulin
receptor) and elevated expression of CD36, compared with the insulin-sensitive state [115]. It appears that
whereas AT M2 cells (that also express increased levels of CD36) are equipped with enzymes that store or
consume SatFAs, M1 cells preferentially depend on glycolysis for energy. As a result, M1 cells in obese AT
accumulate large lipid droplets and are exposed to the deleterious effects of excess saturated FAs [49]. A
recent study demonstrated that upon uptake, SatFAs serve as a substrate for ceramide synthesis in macro-
phages [116], a fate shared by metabolic organs exposed to nutrient excess [20, 22]. In the absence of suf-
ﬁcient adiponectin-driven ceramidase activity [61], ceramide activates the Nlrp3 inﬂammasome, which in-
duces caspase-1-mediated processing and activation of IL-1α [116]. In addition, deletion of CD36 in hema-
topoietic-derived cells alone was sufﬁce to attenuate adipose IR and macrophage accumulation that results
from consuming a high-fat diet [117].
In short, saturated FAs classically activate AT macrophages through activation of PRR directly,
through activation of cell-surface TLRs and indirectly, through uptake and conversion to ceramide, which
activates the intracellular NLRP3.
Proinﬂammatory cytokines (TNF-α,I L - 1 β) and TLRs signal through IKK and JNK. The latter
kinases induce IR by serine phosphorylation of IRSs and by activating their downstream proinﬂammatory
transcription factors, NF-κB and AP-1. Cell-speciﬁc knockout experiments have established that activation
of IKKβ and JNK1 in monocyte macrophages is sufﬁcient to induce obesity-induced IR and inﬂammation
in metabolic organs, including adipose tissue [118, 119]. These ﬁndings further corroborate the centrality
of M1 signaling in obesity-induced inﬂammation, and IR.
Activation of M1 cells by proinﬂammatory cytokines and FSatFAs has been discussed in detail
(summarized in part in Figure 1). In infection, IFN-γ secreted across the immune synapse forged by
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Th1-polarized CD4+ lymphocytes and antigen-presenting macrophages contributes directly to M1 skewing.
SeveralstudiesnotelaboratedonherehavedemonstratedthatIFN-γ-secreting,Th1lymphocytesparticipate
in M1 specialization, inﬂammation and IR in obese AT [34, 36].
An important caveat to the M1-M2 dichotomy is that in vivo, macrophages generally acquire a mixed
phenotypealongtheM1-M2axis[4,5].Thisalsoappliestomacrophagesthatincreasinglypopulateexpand-
ing adipose. For instance, an increase in CD11c+ macrophages displaying a mixture of M1 (e.g., exhibiting
enhanced IL-1β expression) and M2 (demonstrating enhanced arignase-1 and suppressed iNOS expression)
characteristics was observed in AT from mice fed a high-fat diet [120]. Other studies have also demonstrated
the presence of various mixed phenotypes in obese AT and have called into question the strict depiction of
M1 cells as increasing in number and inducing IR and of M2 cells as insulin sensitizers but dwindling
in number as AT expands [44, 120]. Clearly some of the discrepancies may be attributed to the different
diets (e.g., 30% versus 60% fat), mouse species, and methods employed in the many studies investigating
this issue. Indeed, recent expert opinion maintains that the M1/M2 paradigm is a reasonable starting point
to conceptualize and investigate macrophages’ involvement in AT function. Nevertheless, a more accurate
depiction necessarily includes several mixed phenotypes associated with human and rodent obesity [33].
5. IMMUNO-METABOLISM: METABOLIC MODES OF M1, M2, AND Mres CELLS
Historically, immunity and energy metabolism are considered to be distinct capabilities, subserved by
different cell-types and differentially regulated to respond to an array of departures from homeostasis.
More recently, speciﬁc modes of immunity and energy metabolism are being interrelated at the molecular,
cellular, organ and organism level. The coupling of AT responsiveness to insulin to the phenotype of local
macrophages is a striking example of immune and metabolic cross-talk. The exciting interdisciplinary ﬁeld
of immuno-metabolism focuses on the coregulation of hematopoietic cell types’ speciﬁc immune function,
and their mode of ATP generation [121]. It appears that in the course of the inﬂammatory response,
macrophages switch their metabolic mode in conjunction and in cooperation with the timely transition
from the M1 to the M2, and eventually to the Mres phenotype.
The dependence of neutrophils and macrophages on glycolysis, rather than mitochondrial ATP
production, even in normoxia, was ﬁrst demonstrated close to a century ago [122]. Since then, the hypoxia-
inducible factor (HIF-1) transcriptional complex has emerged as a critical regulator of cellular and systemic
responses to low oxygen levels. Oxygen tension is low in inﬂamed, edematous tissues, curtailing oxidative
metabolism that could provide ATP for the energy-requiring functions of phagocytes recruited to a site of
infection: migration, protein synthesis, and so forth. Hypoxia allows the HIF-1α subunit to be translocated
to the nucleus, where it forms a dimer with HIF-1β. The HIF heterodimer binds hypoxic-response elements
in the promoter region of genes that promote phagocyte energy generation, inﬂammatory and bactericidal
activities, and survival. The HIF-regulated genes function together to orchestrate the metabolic shift to
anaerobic glycolysis: increased insulin-independent uptake of glucose (GLUT-1), glycolysis to pyruvate
(e.g., M-type pyruvate kinase), and pyruvate conversion to lactate (lactate dehydrogenase) rather than its
entry into the Krebs cycle (pyruvate dehydrogenase (PDH) kinase 1; PDK1) [122]. HIF-1α is intimately
associated with classic macrophage activation: TLR signaling to NF-κB upregulates macrophage HIF-1α
expression [123], HIF-1α induces the synthesis of M1-type cytokines and mediators [124], and the levels
of HIF-1α increase during the differentiation of blood monocytes into tissue macrophages [125]. Hif1−/−
macrophages and rodents produce less lactate and ATP and exhibit impairment of tissue extravasation and
intracellular killing of phagocytosed microorganisms, both ATP-requiring processes [126]. Thus, HIF-1α
is instrumental in macrophage (and neutrophil) metabolic adaption to the challenge of performing ATP-
dependent immune functions despite the low ambient oxygen that characterizes acutely inﬂamed tissues.
HIF-1α also defers programmed neutrophil apoptosis [127], a signal for efferocytosis by macrophages and
the consequent transition to M2 and Mres phenotypes [14]. Interestingly, M1 stimulating factors, such
as LPS and IFN-γ, enhanced glycolysis in macrophages independently of HIF-1 (through the induction
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of a more active phosphofructokinase (PFK) isoform), yet M2 stimulants failed to elicit such a response
[128, 129].
The intense burst of anaerobic metabolism in acute-phase macrophages has been likened to that
occurring in “fast-twitch” muscle ﬁbers that allow us to sprint short distances. Applying this analogy, the
later stages of inﬂammation and tissue remodeling necessitate an endurance mode of activity, supported
by on-going aerobic metabolism. We previously described how Th2-type cytokines, PPAR-γ,a n dP G C - 1 β
cooperate to induce the molecular machinery that drives the immune functions and metabolism in M2
macrophages. In a sense, the metabolic capacity of AT M2 cells to uptake, esterify, and oxidize FSatFA
constitutes a unique immune function, that is, the removal of FSatFA so as to avoid M1 activation and
IR. Furthermore, M2 cells that arise as inﬂammation subsides may undergo a gradual increase in tissue
oxygen tension, allowing the utilization of FA to generate ATP. Hence, induction of enzymes involved in
FA oxidation (stimulation of macrophages with IL-4 increased the rate of β-oxidation by ∼200%) would
provide energy for M2 cells to reestablish tissue homeostasis [1]. Pharmacologic inactivation of oxidative
metabolism (fatty acid oxidation, oxidative phosphorylation, or mitochondrial respiration) markedly
reduced the IL-4-induced expression of arginase-1, dectin-1, and the mannose receptor, but not LPS- and
IFN-γ-induced production of M1 markers. This suggests tight coupling of the metabolic and immune
functions of M2 macrophages. In contrast to the metabolic mode of M1 cells (anaerobic glycolysis) that
supports the latter’s phenotype-speciﬁc immune function through provision of ATP, inhibition of oxidative
metabolism in macrophages stimulated by Th2 cytokines had little impact on ATP levels. Further studies
are needed to determine how oxidative metabolism is coupled to M2 immune function [1].
The pathways regulating M2 immune and metabolic modes also intersect to provide PPAR-γ
(Figures 1 and 2)a n dP P A R - δ with a ligand they require in order to initiate transcription. Th2 cytokines
induce 15-LO in M2 cells in a STAT6-dependent manner [65, 66, 68]. Furthermore, engulfed apoptotic
neutrophils also induce 12/15-LO expression by macrophages [9, 14]. 15-HETE isomers and 17S-HDHA
are intermediate metabolites in the 12/15-LO-dependent synthesis of SPM from the long-chain polyunsat-
urated FA, AA, EPA, and DHA [65, 66, 68, 71, 130]. Whereas SPM act on G-protein coupled receptors
in a autocrine and paracrine manner, 15-HETE isomers 17S-HDHA are intracrine mediators, potently
binding to both PPAR-γ [53, 71]a n dP P A R - δ [130]. Furthermore, PPAR-δ is responsible for enhancing
the expression of macrophage receptors for apoptotic cells, in addition to boosting aerobic metabolism
and mitochondrial biogenesis. Lipids derived from engulfed apoptotic cells also activate PPAR-δ, thereby
reinforcing efferocytosis and coupling it to aerobic metabolism [131], until satiety is attained.
AsevidenceoftheexistenceanduniquenessofMresgathers,itistemptingtospeculatethattheemer-
gence of this phenotype is regulated by distinct pathways and transcription factors. Furthermore, con-
sidering that CD11blow cells are destined to egress through the lymphatic system—where oxygen tension
is low—a switch from the oxidative mode of M2 cells to oxygen-independent metabolism seems plausible.
Even if this is the case, it is unlikely that the transition to glycolysis is mediated through HIF-1α,a st h i s
would be presumably associated with enhanced TLR-NF-κB signaling. Rather, we found Mres cells to
be hypo-responsive to LPS and other TLR ligands [14]. We, therefore, speculate that a transcription fac-
tor(s) other than HIF-1 and PPAR-γ respond to resolution-promoting signals to mediate the metabolic and
resolution phase functions of Mres. Identifying such a factor would open a new avenue for combating
relentless inﬂammation.
6. FUTURE DIRECTIONS
The association of improper nutrition, obesity, and inﬂammatory leukocyte phenotypes in the immune sys-
tem, and particularly in fat tissue macrophages, highlights the role of macrophages in the development
of metabolic disorders, like diabetes mellitus and insulin resistance. Moreover, the dominance of M2-like
macrophages in lean fat stores and the differential metabolic pathways expressed in M1 and M2 macro-
phages suggests an intimate crosstalk between adipose tissue macrophages and their surrounding adipo-
cytes. The identiﬁcation of a new macrophage phenotype, that is, associated with resolution of acute,
2520TheScientiﬁcWorldJOURNAL (2011) 11, 2509–2529
CD11b
CD11b
CD11b
CD18
CD18
CD18
CD11b
CD11b
CD11b
CD18
CD18
CD18
p50 p65 HIF1-α
M1 mediators
M1 mediators
GLUT1
PK-M
LDH-A
PDK1
HIF-1α HIF-1β
Hypoxia
+
+
+
+ + +
+ Pura
G
l
y
c
o
l
y
s
i
s
ADP
ATP
PK-M
Pyruvate
Pyruvate
Lactate
LDH-A
PDK1 PDH
GLUT1
FFA
CD36
IL-4, IL-13
Early efferocytosis
AA SPM
EPA
DHA
15-LO
ATP
ADP
15-HETE, 17S-HDHA
PPAR γ PPAR γ RXR RXR
PPAR δ
PPAR δ
15-LO
Glycolysis
Glucose
Glucose
Glucose
Pyruvate
Pyruvate
STAT6 STAT6
M2 mediators
II I
LCAD
LCAD
CD36
Citrate synthase
ATP synthase
Apoptosis receptor
Cirate synthase
PDH
Mres
Acetyl-CoA
IIIIV Oxidative phosphorylation:
O2
H2O
NADH/FADH
β-oxidation
Acyl-CoA
Time
Krebs
ATP ADP
M1
Satiating efferocytosis
?
?
?
CD 18
CD11b
cycle
C
D
1
1
b
C
D
1
8
FIGURE 2: Coregulation of immune phenotype and metabolic mode in macrophages. Recruited macro-
phages display striking phenotype plasticity in the course of acute, spontaneously resolving inﬂammation.
Upon exudation into edematous, hypoxic tissue, macrophages initially acquire the proinﬂam-matory and mi-
crobicidal M1 phenotype and depend on anaerobic glycolysis for ATP. Pathogen-associated molecular pat-
terns, Th1-type cytokines (not shown), and hypoxia-sensitive transcription factors (HIF-1 and Pur, see text
for details) cooperate to induce the expression both of M1 mediators (e.g., cytokines, iNOS, CD11b/CD18)
and of the proteins/enzymes that perform anaerobic glycolysis. The insulin-independent glucose transporter
(GLUT 1) facilitates glucose uptake; pyruvate kinase catalyzes pyruvate synthesis, lactate dehydrogenase
produces lactate from pyruvate and generates NAD+ (required for further glycolysis). PDH-kinase inhibits
pyruvate dehydrogenase, thereby diverting pyruvate away from the Krebs cycle, and towards lactate. With
the clearance of microbes and ablation of edema, specialized proresolution media-tors (SPM), Th2-type
cytokines, and the uptake of apoptotic neutrophils (early efferocytosis) produce a phenotype switch to the
M2 macrophage. IL-4 and IL-13 activate STAT6 transcriptive activity, inducing not only M2 signatures (e.g.,
nonopsonic endocytic receptors) but also two PPAR isoforms and 12/15-LO. The latter synthesizes SPMs—
which promote further nonphlogistic recruitment and efferocytosis by macrophages—and intermediate
metabolites (15-HETE and 17S-HDHA) that are necessary for PPAR activation. Lipids from engulfed
neutrophils also provide PPARδ ligands. The PPARs in turn orchestrate mitochondrial biogenesis and
the metabolic shift to aerobic metabolism of glucose and particularly fatty acids. PPARδ also reinforces
efferocytosis by inducing receptors for apoptotic cells. Upregulated metabolic proteins/enzymes include fatty
acid translocator CD36, enzymes that catalyze β-oxidation of fatty acids (e.g., LCAD-Long Chain Acyl CoA
Dehydrogenase), Krebs cycle enzymes (e.g., citrate synthase), pyruvate dehydrogenase, which enables
glycolysis-derived pyruvate to enter the Krebs cycle, and constituents of the Electron Transport Chain
that perform oxidative phosphorylation. Inhibition of these metabolic pathways hampers M2 function [1].
Handling of fatty acids by adipose tissue M2 constitutes a unique metabolic func-tion in that cells up-take,
catabolize or esterify (not shown) fatty acids released by adipocytes, thereby constraining the level of these
potentially harmful molecules within a normal range. On-going efferocytosis “satiates” the macrophage that
ceases cell engulfment and promotes the resolution of inﬂammation, that is, phenotype switching to Mres
(CD11blow). The metabolic mode and signaling cascades that regulate immune and metabolic functions of
Mres remain to be elucidated.
2521TheScientiﬁcWorldJOURNAL (2011) 11, 2509–2529
spontaneously-resolving inﬂammation and that may be induced (through DHA administration) in chronic,
metabolic-associated inﬂammation, suggests that these macrophages might play beneﬁcial regulatory roles
in additional diseases characterized by an inﬂammatory response of excessive intensity or duration. Further
studies are required to determine whether this is indeed the case and whether Mres are directly involved in
controlling adipocyte function in the lean state and during weight loss. Moreover, it will be important to
determine whether the broad change in macrophage metabolic pathways during polarization and conversion
between phenotypes is essential for these phenotype switches or is merely a consequence of the adaptation
of the macrophage to the new functions and environments it has taken upon itself.
ABBREVIATIONS
IR: Insulin resistance
PKC: Protein kinase C
IRS: Insulin receptor substrate
AT: Adipose tissue
WAT: White adipose tissue
ATM: Adipose tissue macrophage
mTOR: Mammalian target of rapamycin
FA: Fatty acid
FFA: Free fatty acid
FSatFA: Free saturated fatty acid
DM: Diabetes mellitus
Mres: Resolution-promoting macrophage
IFN-γ: Interferon-γ
LPS: Lipopolysaccharide
TNF-α: Tumor necrosis factor-α
CCL2: Chemokine (C-C motif) ligand 2
MCP-1: Monocyte chemotactic Protein 1
EPA: Eicosapentaenoic acid
DHA: Docosahexaenoic acid
PPAR: Peroxisome-proliferator activating receptor
PGC: Peroxisome proliferator-activated receptor-gamma coactivator
DGAT: Diacyl-glycerol acyl-transferase
LCAD: Long chain acyl CoA dehydrogenase
Nlrp3: Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3
PFK: Phosphofructokinase
SPM: Specialized proresolving lipid mediators
12/15-LO: 12/15-lipoxygenase
17S-HDHA: 17S-hydroxy-DHA
PUFA: Polyunsaturated fatty acids
cPLA2: Cytosolic phospholipase A2.
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